Authors (in alphabetical order):
Alex De Caluwé, Institut Jules Bordet Katrien Erven, Iridium Kankernetwerk Carine Kirkove, Cliniques Universitaires Saint-Luc Vincent Remouchamps, CHU UCL Namur Liv Veldeman, UZ Gent Caroline Weltens, UZ Leuven
1 BENEFIT OF BREAST RADIOTHERAPY
Curative treatment for breast cancer consists of surgery, radiotherapy and systemic treatments such as chemotherapy, antihormonal therapy and targeted agents. The local treatment options are breast conserving treatment, consisting of breast sparing surgery followed by radiotherapy, and mastectomy with or without radio...
Breast cancer is a disease that affects about 1 in 9 women in Belgium before the age of 75, but it is nowadays a highly curable disease for a majority of people. Radiotherapy plays an essential role in the treatment of breast cancer. When the breast is preserved during surgery, the addition of radiotherapy leads to a clear reduction in the risk of local relapse, i.e. relapse in the treated breast or the draining lymph nodes. For every 4 local relapses prevented, 1 breast cancer death can be prevented. This survival benefit is also seen after mastectomy, but only in lymph node positive patients...
Full article is available in Dutch.
The world of Radiation Therapy requests more attention and proper financing from the government in the battle against cancer.02 Sep, 2019
Article available in Dutch and French.
Mesothelioma patients treated with a high dose of radiation to the affected side of the trunk are twice as likely to survive for two years or longer, according to a new study.
Killing cancer cells with a linear accelerator, or linac, involves extremely precise and movable high energy beams of X-rays or electrons.26 Jun, 2019
This article is available in Dutch and French
Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium.13 Sep, 2018
Source: https://www.ncbi.nlm.nih.gov/pubmed/30190222 There is a gap between optimal and actual use of radiotherapy (RT) in muscle-invasive bladder cancer (MIBC). We investigated the opinions of radiation-oncologists, urologists, and medical oncologists on use of RT in different cases. Barriers and facilitators for applying guidelines were examined.
Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years29 May, 2018
Source of this article: JAMA network Key Points Question How does a climate of expanding targeted and immune therapies but declining funding from the National Institutes of Health affect the conduct of radiotherapy trials compared with other oncological trials? Findings In a cross-sectional analysis of 25 907 interventional oncological trials registered in ClinicalTrials.gov from 2007 to 2017, only 1378 (5.3%) were radiotherapy trials. Sponsorship or funding for radiotherapy trials was significantly less than that for other oncological studies, and the proportion of radiotherapy trials with a sample size of more than 100 patients has decreased in the past decade. Meaning The decline of radiotherapy trials warrants discussion and collaboration among oncologists, funding agencies, industry leaders, and other concerned parties across multiple geographic regions.
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3)05 mrt, 2018
Final results of an international, open-label, multicentre, randomised, phase 3 trial